Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
暂无分享,去创建一个
A. Norman | D. Tait | Gina Brown | A. Wotherspoon | D. Cunningham | P. Ross | N. Tebbutt | I. Chau | M. Hill | J. Oates | A. Massey | G. Brown
[1] Rainer Fietkau,et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Sang‐wook Lee,et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. , 2005, International journal of radiation oncology, biology, physics.
[3] E. Urso,et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Norman,et al. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). , 2005, European journal of cancer.
[5] P. Quirke,et al. The Modern Abdominoperineal Excision: The Next Challenge After Total Mesorectal Excision , 2005, Annals of surgery.
[6] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[7] R. Glynne-Jones,et al. Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). , 2005 .
[8] L. Collette,et al. Preoperative radiation (Preop RT) in rectal cancer: Effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial , 2005 .
[9] N. Wolmark,et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .
[10] R. Greil,et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis , 2005 .
[11] G Brown,et al. Techniques and trouble-shooting in high spatial resolution thin slice MRI for rectal cancer. , 2005, The British journal of radiology.
[12] S. Loi,et al. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial , 2005, British Journal of Cancer.
[13] Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. , 2005, Anticancer research.
[14] S. Miles,et al. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Brown,et al. Preoperative staging of rectal cancer: the MERCURY research project. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[16] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[17] J. Zalcberg,et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer , 2004, British Journal of Cancer.
[18] A. Norman,et al. Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting , 2004 .
[19] T. Conroy,et al. Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial , 2004 .
[20] J. Debus,et al. Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Newcombe,et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.
[22] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[23] T. Conroy,et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Daniel J Sargent,et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Hohenberger,et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] I. Nagtegaal,et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. , 2003, International journal of radiation oncology, biology, physics.
[29] A. Norman,et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer , 2003, British Journal of Cancer.
[30] P. Adeleine,et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R G Newcombe,et al. Preoperative assessment of prognostic factors in rectal cancer using high‐resolution magnetic resonance imaging , 2003, The British journal of surgery.
[32] A. Hinke,et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Barugel,et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. , 2002, International journal of radiation oncology, biology, physics.
[34] K. Song,et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. , 2002, International journal of radiation oncology, biology, physics.
[35] H. Putter,et al. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands , 2002, The British journal of surgery.
[36] P. Quirke,et al. Rates of Circumferential Resection Margin Involvement Vary Between Surgeons and Predict Outcomes in Rectal Cancer Surgery , 2002, Annals of surgery.
[37] I. Nagtegaal,et al. Circumferential Margin Involvement Is Still an Important Predictor of Local Recurrence in Rectal Carcinoma: Not One Millimeter but Two Millimeters Is the Limit , 2002, The American journal of surgical pathology.
[38] T. Mala,et al. Local recurrence after mesorectal excision for rectal cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[39] O Søreide,et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer , 2002, The British journal of surgery.
[40] D J Sargent,et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] H. Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.
[42] P. Romestaing,et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. A’Hern. Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.
[44] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[45] K. Havenga,et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[46] R. Newcombe,et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. , 1999, Radiology.
[47] J. Macfarlane,et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. , 1998, Archives of surgery.
[48] P. Quirke,et al. Role of circumferential margin involvement in the local recurrence of rectal cancer , 1994, The Lancet.
[49] P. Quirke,et al. LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTION Histopathological Study of Lateral Tumour Spread and Surgical Excision , 1986, The Lancet.
[50] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .